Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

106235 reported adverse events

Drugs of this class: EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE ZIDOVUDINE ABACAVIR AND LAMIVUDINE EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE ABACAVIR , LAMIVUDINE AND ZIDOVUDINE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 BONE DENSITY DECREASED 18618
1 CHRONIC KIDNEY DISEASE 11219
2 RENAL FAILURE 9920
3 OSTEONECROSIS 9789
4 BONE LOSS 9514
5 TOOTH LOSS 8881
6 RENAL INJURY 8870
7 PAIN 8612
8 MULTIPLE FRACTURES 8552
9 OSTEOPOROSIS 8156
See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 BONE DEMINERALISATION 409 0.9170
1 CSF HIV ESCAPE SYNDROME 113 0.9040
2 PINEALOBLASTOMA 79 0.8778
3 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 94 0.8545
4 SKELETAL INJURY 7768 0.8200
5 BONE LOSS 9514 0.7733
6 BLOOD HIV RNA INCREASED 756 0.7146
7 IMMUNE RECONSTITUTION SYNDROME 917 0.7098
8 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 147 0.7067
9 BONE DENSITY DECREASED 18618 0.7047
See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]